Clinical Trial Update: A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update announces a Phase 2/Phase 3 study of LNS8801 with or without pembrolizumab in patients with refractory melanoma, and the study is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LNS8801 (LNS8801)

Snippet

Sponsor: Linnaeus Therapeutics, Inc. | Conditions: Melanoma (Skin Cancer), Melanoma Stage IIIB-IV | Phase 2, Phase 3 | Status: RECRUITING